MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2017 International Congress

    Post-hoc analyses of the recommended starting dose for Rytary based on “off” time

    N. Modi, S. Khanna, S. Gupta (Hayward, CA, USA)

    Objective: To determine whether correcting for “off” time duration improves the selection of the final LD dose when converting to extended-release carbidopa-levodopa capsules (ER CD-LD,…
  • 2017 International Congress

    Compulsive sexual behaviour in Parkinson’s disease is associated with higher doses of levodopa

    P. Barbosa, T. Warner, A. Djamshidian (London, United Kingdom)

    Objective: To assess whether compulsive sexual behaviour in individuals with PD is associated with higher doses of levodopa.  Background: The lifetime prevalence of compulsive sexual behaviour…
  • 2017 International Congress

    Dopamine substitution restores effective connectivity between prefrontal and premotor areas in Parkinson’s disease

    P. Loehrer, F. Nettersheim, F. Jung, I. Weber, C. Huber, T. Dembek, E. Pelzer, M. Tittgemeyer, L. Timmermann (Marburg, Germany)

    Objective: To assess influences of dopamine deficiency on the causal interplay within the motor network during bimanual finger tapping in Parkinson's disease (PD) patients. Background:…
  • 2017 International Congress

    Polyneuropathy in patients with Parkinson’s disease from southern Spain treatment with levodopa/carbidopa intestinal gel infusión

    F. Carrillo, S. Jesus, L. Vargas, M. Bernal, M.T. Caceres, A.D. Adarmes, M. Carballo, P. Mir (Seville, Spain)

    Objective: This study main objective is to prospectively report the 10-year incidence of polineuropathy in Parkinson´s disease patients from southern Spain treated with LCIG. Background: Patients with…
  • 2017 International Congress

    Levodopa/carbidopa Intestinal Gel Can Improve Both Motor and Non-Motor Experiences of Daily Living in Parkinson’s Disease: An Open-Label Study

    N. Kovacs, A. Juhász, Z. Aschermann, P. Ács, J. Janszky, M. Kovács, A. Makkos, M. Harmat, D. Tényi, K. Katádi, S. Komoly, A. Takáts, A. Tóth, H. Nagy, P. Klivényi, G. Dibó, L. Dézsi, D. Zádori, Á. Annus, L. Vécsei, L. Varannai (Pécs, Hungary)

    Objective: : Our aim was to determine if the MDS-UPDRS and UDysRS could detect improvement in the experiences of daily living following 1-year LCIG treatment.…
  • 2017 International Congress

    Tremor as the first symptom reported by Parkinson’s disease patients is a predictor of future motor subtype and levodopa-induced dyskinesia.

    A. Schumacher-Schuh, F. Drumond, J. Leal, M. Dotto, S. Machado, C. Rieder (Porto Alegre, Brazil)

    Objective: To better delineate risk profiles for the development of levodopa-induced dyskinesia is an important effort that can help understand this phenomenon and could impact…
  • 2017 International Congress

    The SYNAPSES study  (StudY to observe SafiNAmide in clinical Practice during the firSt post-commErcialization phaSe): methodology and results from the European feasibility survey

    G. Camattari, G. Abbruzzese, W. Jost, J. Kulisevsky, V. Tubazio, L. Simoni, The SYNAPSES investigators (Bresso, Italy)

    Objective: Here we present the design of a Drug Utilization Study of safinamide in the first post-commercialization phase and report results of the study feasibility…
  • 2017 International Congress

    Intrajejunal levodopa infusion (ILI) for Parkinson’s Disease (PD): A Canadian Experience

    P. Podgorny, P. McCann, K. Toore, G. Tremain, A. Lazarescu, O. Suchowersky (Edmonton, AB, Canada)

    Objective: To review the benefits and complications of ILI for PD in a tertiary movement disorders center in Canada. Background: ILI has been in use…
  • 2017 International Congress

    The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease

    M. Nagai, M. Kubo, H. Iwaki, R. Ando, M. Nomoto (Ehime, Japan)

    Objective: The levodopa tablet is prone to dissolve in acidic conditions. We investigated whether gastric acid suppressants (histamine-2 receptor antagonists or proton pump inhibitors) and…
  • 2017 International Congress

    Tremor-Dominant Clinical Phenotype is Associated with Low Risk of Levodopa-Induced Dyskinesia in Parkinson’s Disease

    B. Santos-Lobato, M. Capelari, N. Novaretti, Â. Vieira, V. Borges, H. Ferraz, I. Mata, C. Zabetian, V. Tumas (Ribeirão Preto, Brazil)

    Objective:  To evaluate possible associations between epidemiological and clinical data with risk of levodopa-induced dyskinesias (LID) onset in  Parkinson’s disease (PD) patients. Background: LID are…
  • « Previous Page
  • 1
  • …
  • 50
  • 51
  • 52
  • 53
  • 54
  • …
  • 62
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley